2019 R&D portfolio in review: Sleeping sickness

Added to the WHO Essential Medicines List in 2019, the first all-oral cure for sleeping sickness, fexinidazole, is now being donated by Sanofi to WHO for distribution in T.b. gambiense-endemic countries. DNDi is supporting pharmacovigilance and training to scale up access to this new treatment while advancing clinical development of acoziborole – a potentially game-changing, single-dose oral treatment that could provide an even better treatment option and facilitate sustained elimination of the disease.

DNDi receives $29 million to fast-track the development of drugs to help eliminate sleeping sickness and river blindness

Geneva/Seattle – 25  November 2019

DNDi has been awarded $29.2 million to accelerate the development of innovative new drugs for patients in sub-Saharan Africa with sleeping sickness (human African trypanosomiasis – $15 million) and river blindness (onchocerciasis – $14.2 million) by the Bill & Melinda Gates Foundation These two parasitic diseases could be eliminated if new patient care tools are brought to bear.